Artwork

Content provided by Clinical Care Options LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Expert Discussions: Novel Agents Targeting Residual Inflammatory Risk in ASCVD and CKD

15:28
 
Share
 

Manage episode 436382945 series 3242427
Content provided by Clinical Care Options LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.  

 Episode outline:  

  • Colchicine: inhibition of NLRP3 inflammasome assembly/activation
  • Canakinumab (anti–IL-1β monoclonal antibody)
  • Ziltivekimab (anti–IL-6 monoclonal antibody)
  • Other emerging targets/therapies

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

  continue reading

29 episodes

Artwork
iconShare
 
Manage episode 436382945 series 3242427
Content provided by Clinical Care Options LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.  

 Episode outline:  

  • Colchicine: inhibition of NLRP3 inflammasome assembly/activation
  • Canakinumab (anti–IL-1β monoclonal antibody)
  • Ziltivekimab (anti–IL-6 monoclonal antibody)
  • Other emerging targets/therapies

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:  

  continue reading

29 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide